These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 26843061)

  • 21. Quantitative Measurement of the Direct Public Health Impact of Medicines Withdrawals in Europe: Development of a Modelling Method and Proof-of-Concept Study to Estimate the Morbidity and Mortality Prevented by Regulatory Action.
    Lane S; Lynn E; Shakir S
    Pharmacoepidemiol Drug Saf; 2024 Sep; 33(9):e70003. PubMed ID: 39212104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Drugs associated with hepatotoxicity and their reporting frequency of liver adverse events in VigiBase: unified list based on international collaborative work.
    Suzuki A; Andrade RJ; Bjornsson E; Lucena MI; Lee WM; Yuen NA; Hunt CM; Freston JW
    Drug Saf; 2010 Jun; 33(6):503-22. PubMed ID: 20486732
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is PEGylation of Drugs Associated with Hypersensitivity Reactions? An Analysis of the Italian National Spontaneous Adverse Drug Reaction Reporting System.
    Crisafulli S; Cutroneo PM; Luxi N; Fontana A; Ferrajolo C; Marchione P; Sottosanti L; Zanoni G; Moretti U; Franzè S; Minghetti P; Trifirò G
    Drug Saf; 2023 Apr; 46(4):343-355. PubMed ID: 36790561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suspected adverse drug reactions reported for Brazilian children: cross-sectional study.
    Lima EDC; Matos GC; Vieira JML; Gonçalves ICDCR; Cabral LM; Turner MA
    J Pediatr (Rio J); 2019; 95(6):682-688. PubMed ID: 30030984
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.
    Olivier P; Montastruc JL
    Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):808-12. PubMed ID: 16700082
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Withdrawn medicines included in the essential medicines lists of 136 countries.
    Charles O; Onakpoya I; Benipal S; Woods H; Bali A; Aronson JK; Heneghan C; Persaud N
    PLoS One; 2019; 14(12):e0225429. PubMed ID: 31791048
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of factors related to the occurrence of important drug-specific postmarketing safety-related regulatory actions: A cohort study focused on first-in-class drugs.
    Ikeda J; Kaneko M; Narukawa M
    Pharmacoepidemiol Drug Saf; 2018 Dec; 27(12):1393-1401. PubMed ID: 30094880
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-associated cardiovascular risks: A retrospective evaluation of withdrawn drugs.
    Kocadal K; Saygi S; Alkas FB; Sardas S
    North Clin Istanb; 2019; 6(2):196-202. PubMed ID: 31297490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Direct reporting of adverse drug reactions by healthcare consumers in Africa: a narrative review.
    Adedeji-Adenola H; Nlooto M
    Int J Clin Pharm; 2021 Feb; 43(1):11-24. PubMed ID: 32902780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. When More Is Less: An Exploratory Study of the Precautionary Reporting Bias and Its Impact on Safety Signal Detection.
    Klein K; Scholl JHG; De Bruin ML; van Puijenbroek EP; Leufkens HGM; Stolk P
    Clin Pharmacol Ther; 2018 Feb; 103(2):296-303. PubMed ID: 28913827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
    Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
    Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Can pharmacogenetics help rescue drugs withdrawn from the market?
    Shah RR
    Pharmacogenomics; 2006 Sep; 7(6):889-908. PubMed ID: 16981848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends.
    Issa AM; Phillips KA; Van Bebber S; Nidamarthy HG; Lasser KE; Haas JS; Alldredge BK; Wachter RM; Bates DW
    Curr Drug Saf; 2007 Sep; 2(3):177-85. PubMed ID: 18690965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative regulatory performance on introduction & withdrawal of drugs in India and EU/internationally.
    Kshirsagar NA; Bachhav SS
    Int J Risk Saf Med; 2013; 25(4):235-8. PubMed ID: 24305562
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety surveillance of longitudinal databases: methodological considerations.
    Norén GN; Hopstadius J; Bate A; Edwards IR
    Pharmacoepidemiol Drug Saf; 2011 Jul; 20(7):714-7. PubMed ID: 21638520
    [No Abstract]   [Full Text] [Related]  

  • 38. Safety surveillance of longitudinal databases: further methodological considerations.
    Schuemie MJ
    Pharmacoepidemiol Drug Saf; 2012 Jun; 21(6):670-2; author reply 673-5. PubMed ID: 22678687
    [No Abstract]   [Full Text] [Related]  

  • 39. Registries in European post-marketing surveillance: a retrospective analysis of centrally approved products, 2005-2013.
    Bouvy JC; Blake K; Slattery J; De Bruin ML; Arlett P; Kurz X
    Pharmacoepidemiol Drug Saf; 2017 Dec; 26(12):1442-1450. PubMed ID: 28345151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.
    Spelsberg A; Prugger C; Doshi P; Ostrowski K; Witte T; Hüsgen D; Keil U;
    BMJ; 2017 Feb; 356():j337. PubMed ID: 28174182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.